FDASIA Has Low Profile in Pharma Earnings Calls
This article was originally published in RPM Report
Executive Summary
In the wave of pharma earnings calls after the July 9 signing of the FDA Safety & Innovation Act, the good news is that the law did not appear to be a material event for most companies and investors. The lack of attention to the law by management teams and analysts is a quiet reaffirmation that this iteration of the user fee reauthorization went smoothly for industry and the regulatory agency.
You may also be interested in...
Getting a Jump on PDUFA V: Fast Start on REMS, Patient Input – And Longer Reviews
The new Prescription Drug User Fee Act Program doesn’t take effect until October 1, but FDA has been getting moving on some key elements of the program since before the final negotiations began on Capitol Hill. FDA will need to move fast to meet the many policy deadlines set by the agreement negotiated with industry.
The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V
The Infectious Diseases Society of America’s “Special Population” approval mechanism has proponents within FDA and industry. That makes it look like a good balancing proposal to complement the market incentives for anti-infectives being pushed under the GAIN Act add-on to PDUFA V. There is one big hurdle, however: GAIN’s major legislative proponent, Rep. Phil Gingrey (R-GA) does not like the limitations on use post-approval.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.